Influence of systemic sclerosis on periodontal health: A case-control study

J Clin Periodontol. 2023 Oct;50(10):1348-1359. doi: 10.1111/jcpe.13846. Epub 2023 Jul 11.

Abstract

Aim: Patients with systemic sclerosis (SSc) present various clinical and radiological oral manifestations. However, precise evaluation of the oral features associated with diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc) is limited. The objective of this study was to evaluate the periodontal ligament (PDL) surface in SSc patients in comparison with controls. Assessment of oral-health-related quality of life (OHRQoL) and the levels of different biomarkers in the gingival crevicular fluid (GCF) was performed.

Materials and methods: SSc patients and matched controls underwent standardized oral examination and cone-beam computed tomography (CBCT). Levels of interleukin-6 (IL-6), chemokine (C-X-C motif) ligand 4 (CXCL-4) and matrix metalloproteinase-9 (MMP-9) in the GCF were determined by enzyme-linked immunosorbent assay. PDL surface was measured on CBCT axial views. OHRQoL was quantified using the Mouth Handicap in SSc Scale (MHISS).

Results: Thirty-nine SSc patients and 39 controls were included. SSc patients exhibited increased PDL surface, higher number of missing teeth as well as elevated IL-6, MMP-9 and CXCL-4 levels. Reduced mouth opening was observed in dcSSc but not in lcSSc patients. MHISS score was higher in dcSSc than in lcSSc patients. Although worse periodontal parameters were found in both subgroups compared with controls, dcSSc patients presented lower gingival inflammation.

Conclusions: SSc is associated with PDL space widening, impaired oral health and OHRQoL.

Trial registration: ClinicalTrials.gov NCT02371005.

Keywords: autoimmunity; gingival crevicular fluid; periodontal diseases; periodontitis; systemic sclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Humans
  • Interleukin-6
  • Matrix Metalloproteinase 9*
  • Quality of Life
  • Scleroderma, Systemic* / complications

Substances

  • Matrix Metalloproteinase 9
  • Interleukin-6

Associated data

  • ClinicalTrials.gov/NCT02371005